Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers.

Abstract excerpt

Selective BRAF inhibitors have demonstrated significant clinical benefit in melanoma patients harboring oncogenic BRAF mutations. However, the majority of such patients either exhibit de novo resistance from the beginning of the treatment or acquire resistance and eventually relapse. Despite tremendous progress in understanding the underlying mechanisms of resistance, overcoming resistance to BRAF inhibitors...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Protein Kinase Inhibitors
• Share to Cyclin-Dependent Kinase 4